Clinical trial
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet…
NCT00385138 · The Medicines Company, Industry · Terminated
Key facts
| NCT number | NCT00385138 |
|---|---|
| Title | Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Official title | A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI). |
| Acronym | Platform |
| Lead sponsor | The Medicines Company, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Acute Coronary Syndrome (ACS) |
| Intervention type | Drug |
| Interventions | Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion |
| Enrollment | 5,364 |
| Start date | Sep 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | May 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: